Bayer Saddles Up For Bicycle Radioconjugate Pact
Second Big Pharma Partner In Two Months For UK Biotech
The German major is paying $45m upfront to get access to Bicycle’s synthetic peptides for the discovery and development of multiple targeted radioconjugates in oncology.
